爱德华兹生命科学（EW）在夜盘交易中股价大涨5.76%，引发市场关注。
消息面上，公司公布了超出预期的第二季度业绩。得益于用于复杂心脏手术的人工心脏瓣膜需求强劲，其季度利润和营收均高于分析师预期。具体来看，核心产品经导管主动脉瓣置换装置（TAVR）本季度销售额同比增长11.3%，达到12.6亿美元，远超市场预期的12.3亿美元。
此外，公司还将2026年TAVR设备销售额增长预期的下限从7%上调至8%，并维持了年度调整后利润预期。强劲的业绩和乐观的指引共同推动了股价在夜盘时段走高。
爱德华兹生命科学（EW）在夜盘交易中股价大涨5.76%，引发市场关注。
消息面上，公司公布了超出预期的第二季度业绩。得益于用于复杂心脏手术的人工心脏瓣膜需求强劲，其季度利润和营收均高于分析师预期。具体来看，核心产品经导管主动脉瓣置换装置（TAVR）本季度销售额同比增长11.3%，达到12.6亿美元，远超市场预期的12.3亿美元。
此外，公司还将2026年TAVR设备销售额增长预期的下限从7%上调至8%，并维持了年度调整后利润预期。强劲的业绩和乐观的指引共同推动了股价在夜盘时段走高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.